GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Kemas kini terakhir: 25 Nov, 6:10PM

90.49

0.30 (0.33%)

  • 1H 0.33%
  • 5H -2.05%
  • 1B 0.81%
  • 6B 28.05%
  • Tahun Ke Tarikh 8.71%
  • 1T 14.65%
  • 5T 35.57%
Penutupan Terdahulu 90.19
Buka 90.93
Jumlah Dagangan 10,641,237
Purata Dagangan (3B) 6,668,701
Modal Pasaran 112,774,963,200
Harga / Pendapatan (P/E TTM) 1,005.44
Harga / Pendapatan (P/E Ke hadapan) 12.22
Harga / Jualan (P/S) 4.06
Harga / Buku (P/B) 6.21
Julat 52 Minggu
62.07 (-31%) — 98.90 (9%)
Tarikh Pendapatan 4 Feb 2025 - 10 Feb 2025
Hasil Dividen (DY TTM) 3.40%
Margin Keuntungan 0.44%
Margin Operasi (TTM) 41.96%
EPS Cair (TTM) 0.090
Pertumbuhan Hasil Suku Tahunan (YOY) 7.00%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -42.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 126.42%
Nisbah Semasa (MRQ) 1.26
Aliran Tunai Operasi (OCF TTM) 10.02 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 9.08 B
Pulangan Atas Aset (ROA TTM) 11.96%
Pulangan Atas Ekuiti (ROE TTM) 0.56%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menaik
Drug Manufacturers - General (Global) Menaik Menaik
Stok Gilead Sciences, Inc. Menaik Menaik

AISkor Stockmoo

-0.9
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam -2.5
Volatiliti Harga -0.5
Purata Bergerak Teknikal -2.5
Osilator Teknikal -0.5
Purata -0.90

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GILD 113 B 3.40% 1,005.44 6.21
AMGN 143 B 3.38% 34.01 18.81
AZN 240 B 1.93% 37.45 5.19
SNY 120 B 8.54% 25.24 1.55
GRFS 6 B - 32.20 0.830
BIIB 23 B - 14.35 1.31

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.12%
% Dimiliki oleh Institusi 88.40%
Julat 52 Minggu
62.07 (-31%) — 98.90 (9%)
Julat Harga Sasaran
80.00 (-11%) — 125.00 (38%)
Tinggi 125.00 (Citigroup, 38.14%) Beli
Median 101.00 (11.62%)
Rendah 80.00 (Cantor Fitzgerald, -11.59%) Pegang
Purata 100.44 (11.00%)
Jumlah 11 Beli, 7 Pegang
Harga Purata @ Panggilan 93.61
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Cantor Fitzgerald 11 Dec 2024 80.00 (-11.59%) Pegang 92.38
07 Nov 2024 80.00 (-11.59%) Pegang 97.90
RBC Capital 11 Dec 2024 84.00 (-7.17%) Pegang 92.38
18 Nov 2024 84.00 (-7.17%) Pegang 88.46
B of A Securities 10 Dec 2024 109.00 (20.46%) Beli 92.34
Oppenheimer 10 Dec 2024 115.00 (27.09%) Beli 92.34
07 Nov 2024 105.00 (16.03%) Beli 97.90
Mizuho 21 Nov 2024 100.00 (10.51%) Beli 89.76
UBS 21 Nov 2024 96.00 (6.09%) Pegang 89.76
Wolfe Research 15 Nov 2024 110.00 (21.56%) Beli 88.40
Citigroup 14 Nov 2024 125.00 (38.14%) Beli 92.11
Truist Securities 08 Nov 2024 97.00 (7.19%) Pegang 96.57
BMO Capital 07 Nov 2024 102.00 (12.72%) Beli 97.90
17 Oct 2024 94.00 (3.88%) Beli 87.36
Baird 07 Nov 2024 95.00 (4.98%) Pegang 97.90
Barclays 07 Nov 2024 95.00 (4.98%) Pegang 97.90
07 Oct 2024 84.00 (-7.17%) Pegang 84.43
Goldman Sachs 07 Nov 2024 84.00 (-7.17%) Pegang 97.90
JP Morgan 07 Nov 2024 105.00 (16.03%) Beli 97.90
09 Oct 2024 100.00 (10.51%) Beli 86.14
Piper Sandler 07 Nov 2024 105.00 (16.03%) Beli 97.90
Wells Fargo 07 Nov 2024 105.00 (16.03%) Beli 97.90
07 Oct 2024 100.00 (10.51%) Beli 84.43
Leerink Partners 21 Oct 2024 96.00 (6.09%) Beli 86.29
Bernstein 17 Oct 2024 105.00 (16.03%) Beli 87.36
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
DICKINSON ANDREW D - 92.34 -1,686 -155,685
MERCIER JOHANNA - 92.34 -1,739 -160,579
O'DAY DANIEL PATRICK - 92.34 -4,762 -439,723
PARSEY MERDAD - 92.34 -1,771 -163,534
PATTERSON SANDRA - 92.10 -565 -52,097
TELMAN DEBORAH H - 92.34 -306 -28,256
Jumlah Keseluruhan Kuantiti Bersih -10,829
Jumlah Keseluruhan Nilai Bersih ($) -999,875
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 92.27
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
PATTERSON SANDRA Pegawai 13 Dec 2024 Dibuang (-) 157 91.86 14,422
PATTERSON SANDRA Pegawai 13 Dec 2024 Pelaksanaan pilihan 157 - -
DICKINSON ANDREW D Pegawai 10 Dec 2024 Dibuang (-) 1,686 92.34 155,685
DICKINSON ANDREW D Pegawai 10 Dec 2024 Pelaksanaan pilihan 3,640 - -
MERCIER JOHANNA Pegawai 10 Dec 2024 Dibuang (-) 1,739 92.34 160,579
MERCIER JOHANNA Pegawai 10 Dec 2024 Pelaksanaan pilihan 3,752 - -
O'DAY DANIEL PATRICK Pegawai 10 Dec 2024 Dibuang (-) 4,762 92.34 439,723
O'DAY DANIEL PATRICK Pegawai 10 Dec 2024 Pelaksanaan pilihan 10,295 - -
PARSEY MERDAD Pegawai 10 Dec 2024 Dibuang (-) 1,771 92.34 163,534
PARSEY MERDAD Pegawai 10 Dec 2024 Pelaksanaan pilihan 3,820 - -
TELMAN DEBORAH H Pegawai 10 Dec 2024 Dibuang (-) 306 92.34 28,256
TELMAN DEBORAH H Pegawai 10 Dec 2024 Pelaksanaan pilihan 639 - -
PATTERSON SANDRA Pegawai 10 Dec 2024 Dibuang (-) 408 92.34 37,675
PATTERSON SANDRA Pegawai 10 Dec 2024 Pelaksanaan pilihan 901 - -
Papar semua
  • 3M
Tarikh Jenis Butiran
17 Dec 2024 Pengumuman U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
17 Dec 2024 Pengumuman Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
13 Dec 2024 Pengumuman Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
12 Dec 2024 Pengumuman Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
09 Dec 2024 Pengumuman Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
09 Dec 2024 Pengumuman Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
08 Dec 2024 Pengumuman Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
03 Dec 2024 Pengumuman Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
27 Nov 2024 Pengumuman Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
15 Nov 2024 Pengumuman Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
13 Nov 2024 Pengumuman Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
13 Nov 2024 Pengumuman Gilead Prices $3.5 Billion of Senior Unsecured Notes
12 Nov 2024 Pengumuman Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
08 Nov 2024 Pengumuman Gilead Sciences to Present at Upcoming Investor Engagements
07 Nov 2024 Pengumuman Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
06 Nov 2024 Pengumuman Gilead Sciences Announces Third Quarter 2024 Financial Results
05 Nov 2024 Pengumuman Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
31 Oct 2024 Pengumuman AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
22 Oct 2024 Pengumuman Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
19 Oct 2024 Pengumuman Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
09 Oct 2024 Pengumuman Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
09 Oct 2024 Pengumuman Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
07 Oct 2024 Pengumuman Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
02 Oct 2024 Pengumuman Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
02 Oct 2024 Pengumuman Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
Papar semua
Hasil Dividen (DY TTM) 3.40%
Purata Hasil Dividen 5T 3.91%
Nisbah Pembayaran 3,400.00%
Jangkaan Pembayaran Dividen Seterusnya Mar 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
13 Dec 2024 30 Oct 2024 30 Dec 2024 0.77 Tunai
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 Tunai
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 Tunai
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 Tunai
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 Tunai
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 Tunai
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 Tunai
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 Tunai
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 Tunai
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 Tunai
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 Tunai
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 Tunai
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 Tunai
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 Tunai
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 Tunai
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 Tunai
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 Tunai
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 Tunai
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 Tunai
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 Tunai
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 Tunai
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 Tunai
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 Tunai
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 Tunai
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 Tunai
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 Tunai
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 Tunai
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 Tunai
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 Tunai
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 Tunai
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 Tunai
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 Tunai
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 Tunai
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 Tunai
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 Tunai
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 Tunai
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 Tunai
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 Tunai
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2024 3.08 4 3.40
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2024 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda